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The influenza season 2014/15 started in Europe in 
week 50 2014 with influenza A(H3N2) viruses predomi-
nating. The majority of the A(H3N2) viruses character-
ised antigenically and/or genetically differ from the 
northern hemisphere vaccine component which may 
result in reduced vaccine effectiveness for the season. 
We therefore anticipate that this season may be more 
severe than the 2013/14 season. Treating influenza 
with antivirals in addition to prevention with vaccina-
tion will be important.
Influenza activity started increasing in the west-
ern part of the World Health Organization (WHO) 
European Region during week 50 2014, when Malta, 
the Netherlands and Sweden reported medium inten-
sity of influenza activity which refers to usual activ-
ity of influenza season [1]. Rates of influenza-like 
illness (ILI) and/or acute respiratory infection (ARI) 
have continued to increase, and in week 2 2015, 13 
countries (Albania, Finland, France, Greece, Iceland, 
Malta, the Netherlands, Portugal, Slovenia, Spain, 
Sweden, Switzerland, the United Kingdom (UK)) in 
the WHO European Region reported medium intensity 
and Albania, the Netherlands, Portugal, Spain and 
Switzerland had ILI rates above the epidemic thresh-
old for the pre-season [2]. Of the 13 countries report-
ing medium intensity, six (Finland, the Netherlands, 
Portugal, Slovenia, Sweden and the UK (England)) 
reported patterns of widespread activity with labora-
tory-confirmed influenza cases in 50% or more of their 
administrative units (or reporting sites).
Influenza surveillance in Europe
Since October 2014, all 53 Member States of the WHO 
European Region report their epidemiological and viro-
logical influenza surveillance data to The European 
Surveillance System (TESSy), hosted by the European 
Centre for Disease Prevention and Control (ECDC) [1]. 
The data are jointly published with the WHO European 
Regional Office to describe the annual occurrence of 
influenza (timing and spread), its impact and sever-
ity (groups which are most affected), the predominat-
ing influenza type and subtype, as well as analyses of 
virus strains to support the WHO recommendations for 
the composition of seasonal influenza vaccines (www.
flunewseurope.org). The northern hemisphere influ-
enza vaccine composition recommendation is given by 
WHO at the end of February each year.
Influenza surveillance in Europe is mainly based on 
primary care sentinel sites collecting specimens from 
patients with ILI and/or ARI [1,3]. Data are collected 
at the national level and reported to the European 
level according to standardised case definitions [4,5]. 
The national influenza centres perform antigenic and 
genetic characterisation of influenza viruses as well as 
antiviral susceptibility testing of a representative sam-
ple of virus isolates.
In addition to the primary care surveillance, particu-
larly since the 2009 influenza A(H1N1) pandemic, hos-
pital surveillance of laboratory-confirmed influenza 
cases has been conducted, including for this season, 
in Finland, France, Ireland, Spain, Sweden and the UK. 
Additionally, sentinel severe acute respiratory infec-
tion (SARI) surveillance is in place in 13 countries [1].
Virological situation in primary healthcare
The overall proportion of influenza-positive sentinel 
specimens increased from 4% to 39% from week 47 
2014 to week 2 2015, indicating the start of the sea-
son at a similar time to the previous season (Figure 1). 
The season threshold of 10% was exceeded in season 
2011/12 and 2013/14 in week 51, in 2012/13 in week 49, 
and in the current season during week 50 (Figure 1).
In most countries, influenza A(H3N2) virus was the 
dominant subtype in both sentinel and non-sentinel 
specimens in week 2 2015. In the sentinel systems, 
since week 40, 1,134 (10%) of the 11,854 specimens 
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collected in 35 countries tested positive for influenza, 
901 (79%) for type A influenza virus and 233 (21%) for 
type B (Figure 1). Of the 831 type A viruses subtyped, 
688 (83%) were A(H3N2) and 143 (17%) were A(H1N1)
pdm09 by week 2 2015 (Figure 1). The lineage of 87 
type B viruses was determined: six were B/Victoria lin-
eage and 81 B/Yamagata lineage.
 
The antigenic characteristics of 117 influenza viruses 
and the genetic characteristics of 202 influenza 
viruses were reported to TESSy by 16 countries mainly 
in the western countries of the Region. Of 68 influenza 
A(H3N2) viruses antigenically characterised, 40 were 
reported by the national influenza centres as A(H3N2) 
A/Texas/50/2012-like (vaccine-like) and 26 were A/
Switzerland/9715293/2013-like (antigenically different 
from the vaccine); two viruses could not be ascribed 
to an antigenic category. All 21 A(H1N1)pdm09 viruses 
characterised were A/California/7/2009-like (vaccine 
strain). Of the 30 influenza B viruses characterised, 
28 were of the B/Yamagata/16/88-lineage (10 were 
reported as B/Massachusetts/02/2012-like viruses, one 
B/Wisconsin/1/2010-like and 17 B/Phuket/3073/2013-
like) and two were B/Brisbane/60/2008-like viruses of 
the Victoria lineage.
Of the 160 genetically characterised A(H3N2) 
viruses, 110 (69%) fall in two genetic subgroups 
containing antigenic drift variants compared with A/
Texas/50/2012, the vaccine component for the north-
ern hemisphere 2014/15 season [6].
For 63 viruses, Norway, Spain and Sweden reported 
the haemagglutinin gene sequence accession num-
ber for the Global Initiative on Sharing All Influenza 
Data (GISAID) EpiFlu database. The maximum like-
lihood phylogenetic tree of these viruses together 
with the A(H3N2) reference viruses shows that the 
current circulating viruses cluster mainly with the 
genetic subgroups 3C.3, 3C.3a together with the A/
Switzerland/9715293/2013, and 3C.2a with the A/
Hong Kong/5738/2014, and show genetic drift from the 
current vaccine virus (Figure 2). The antigenic drift of 
viruses clustering with the A/Newcastle/22/2014 has 
not yet been shown.
Ninety-three influenza A(H3N2) viruses, 20 A(H1N1)
pdm09 and four influenza B viruses have been 
tested phenotypically or genotypically for neuramini-
dase inhibitor susceptibility. None showed evidence 
of reduced susceptibility to either oseltamivir or 
zanamivir.
Figure 1
Number of influenza virus-positive sentinel specimens by (sub)type and week, and proportion of positive specimens 
compared to three previous seasons, World Health Organization European Region, weeks 40 2014–2 2015 for season 2014/15
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Laboratory-confirmed hospitalised 
influenza cases
Current surveillance systems reporting laboratory-
confirmed hospitalised influenza cases to TESSy, while 
not being representative on a population basis in all 
countries, provide information on groups being hos-
pitalised due to influenza as well as risk factors for 
severe disease. This season, as of week 40 2014, six 
countries with a monitoring system for laboratory-con-
firmed hospitalised influenza cases reported 719 labo-
ratory-confirmed hospitalised cases. In intensive care 
units (ICU), 671 cases were reported: three in Finland, 
101 in France, 20 in Spain, five in Sweden and 542 in 
the UK. In comparison, for season 2013/14, by week 2 
2014, France had reported 77, Ireland two, Spain 227 
and Sweden 11 ICU cases. The UK had not reported a 
single severe case by week 2 2014 and the surveillance 
system there has not changed.
Of the 719 laboratory-confirmed hospitalised influenza 
cases, 682 (95%) were positive for influenza A virus 
(197 subtyped: 149 A(H3N2) and 48 A(H1N1)pdm09) and 
37 (5%) for influenza B virus, which reflects the over-
all predominance of A(H3N2) and co-circulation of the 
A(H1N1)pdm09 and B viruses.
Of the 671 cases admitted to ICU, 642 (96%) were posi-
tive for influenza A virus (170 subtyped: 126 A(H3N2) 
and 44 A(H1N1)pdm09) and 29 (4%) for influenza B 
virus. Half of the cases admitted to ICU for which infor-
mation on age was available (61/128) were aged 65 
years or older. The median age at admission to ICU was 
64 years (mean 61.6 years, range 1–93 years). In the 
2013/14 influenza season (up to week 2 2014 and dur-
ing the whole season), the majority of ICU cases had 
been 40–64 years old, with influenza A(H1N1)pdm09 
virus as the dominating subtype [7].
Discussion and conclusions
The influenza season in Europe has started and contin-
ues to expand according to the clinical, epidemiologi-
cal and virological indicators. The season is dominated 
by influenza A(H3N2) viruses, although both A(H1N1)
pdm09 and B viruses co-circulate. This is similar to the 
influenza activity in the other parts of northern hemi-
sphere, e.g. the United States (US), where the influ-
enza activity has continued to increase with influenza 
A(H3N2) viruses predominating [8].
The last influenza seasons in Europe dominated by 
A(H3N2) viruses were seasons 2011/12 [9,10] and 
2012/13 [3,11], when A(H1N1)pdm09 and A(H3N2) 
viruses co-dominated. These seasons were estimated 
as moderately severe based on ILI/ARI consultation 
rates, although the European Union/European Economic 
Area (EU/EEA) still lacks agreed criteria for severity of 
influenza. The current season has started earlier in 
the US where higher influenza-related hospitalisation 
rates are being reported as compared with the past 
A(H3N2)-dominated seasons [12]. As shown for Europe, 
the 2014/15 season has started at a similar time and 
Figure 2
Maximum likelihood phylogenetic tree of haemagglutinin 
nucleotide sequences (1,063 nucleotides) from influenza 
A(H3N2) viruses reported to the European Surveillance 
System and reference A(H3N2) viruses, weeks 40 2014–1 
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with similar impact in primary care as the previous sea-
son. Since A(H3N2)-dominated seasons usually cause 
more severe outcomes among the elderly and other 
risk groups than A(H1N1)pdm09 or B seasons [13,14], 
the current influenza epidemic in Europe is expected to 
cause an increased number of severe infections, hos-
pitalisations, ICU admissions and deaths in the elderly 
than the 2013/14 influenza season. This has already 
been observed in ICU admissions reported from the UK 
this season in comparison with the previous season.
In September 2014, the WHO consultation and infor-
mation meeting on the composition of influenza virus 
vaccines indicated an emergence of two new genetic 
clades of A(H3N2) viruses (clades 3C.2a and 3C.3a) 
containing antigenic drift viruses of previously circulat-
ing viruses [15]. The US Centers for Disease Control and 
Prevention subsequently posted a health alert network 
notification [16], and ECDC issued a risk assessment 
[17] concerning the continued circulation and transmis-
sion of these viruses.
Based on our analysis and the current knowledge of 
the circulating viruses [18], the northern hemisphere 
vaccine may not offer desired protection against the 
circulating A(H3N2) viruses. However, for the A(H1N1)
pdm09 and B/Victoria lineage viruses, only limited 
drift has been observed and protection against the 
circulating influenza A(H1N1)pdm09 viruses is still con-
ferred by the vaccine.
The vaccine effectiveness for this season for the 
A(H3N2) and possibly the B component is expected to 
be reduced as already seen in the US [19] and in pre-
vious seasons in Europe [20,21]. However, the vaccine 
is anticipated to prevent some infections, improve the 
course or shorten the duration of influenza in infected 
individuals, and is likely to reduce the number of severe 
outcomes and mortality. It therefore remains the meas-
ure of choice to prevent severe illness and possibly 
fatal outcomes in risk groups. The circulating viruses 
are susceptible to the antiviral drugs oseltamivir and 
zanamivir and these drugs are therefore an important 
adjunct in the treatment of influenza.
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